NPPA outcome data
The data on this page relates to applications received in the 2022/2023 financial year.
2022/23 data
The table below gives the number of applications and the result of the application by chemical. The Excel spreadsheet download provides indications (by chemical), where providing this information will not impact anyone's privacy.
2022/23 NPPA data (includes indications) [XLSX, 22 KB]
The searchable web page(external link) currently has 2022/23 data.
Previous data
| Chemical | Approved | Declined | Principles not met |
Withdrawn | Grand Total |
| adalimumab | 11 | - | - | 2 | 13 |
| alpha tocopheryl acetate | 49 | - | - | 1 | 50 |
| anakinra | 9 | - | - | 1 | 10 |
| asparaginase | 7 | - | - | - | 7 |
| atezolizumab | - | - | 6 | 1 | 7 |
| azacitidine | 5 | - | - | - | 5 |
| azithromycin | 1 | - | 1 | 2 | 4 |
| bedaquiline | 11 | - | - | - | 11 |
| bevacizumab | 9 | - | 6 | - | 15 |
| biotin | 6 | - | - | - | 6 |
| blinatumomab | 7 | - | - | 1 | 8 |
| brentuximab vedotin | 17 | - | 1 | - | 18 |
| canakinumab | 4 | - | - | - | 4 |
| cannabinoid | 3 | - | 10 | 1 | 14 |
| ciclosporin eye preparations | 85 | - | 1 | 1 | 87 |
| cinacalcet | - | - | 2 | 2 | 4 |
| continuous glucose monitoring system | 8 | - | 6 | 2 | 16 |
| dabrafenib | 5 | - | - | 1 | 6 |
| dasatinib | 3 | - | - | 1 | 4 |
| deferasirox | 4 | - | 2 | 1 | 7 |
| denosumab | 5 | - | 5 | - | 10 |
| dupilumab | 3 | - | 1 | - | 4 |
| eculizumab | 2 | 1 | 1 | 1 | 5 |
| eltrombopag | 3 | - | - | 1 | 4 |
| enoxaparin sodium | 4 | - | - | 2 | 6 |
| etanercept | 2 | - | 1 | 1 | 4 |
| fenfluramine | 3 | - | 1 | - | 4 |
| galcanezumab | 1 | - | 3 | - | 4 |
| ganciclovir eye preparations | 4 | - | - | - | 4 |
| ibrutinib | 1 | - | 6 | - | 7 |
| imiglucerase | 5 | - | - | - | 5 |
| indomethacin | 4 | - | - | - | 4 |
| infliximab | 7 | - | 4 | - | 11 |
| inotuzumab ozogamicin | 4 | - | - | - | 4 |
| insulin pump consumables | 3 | - | - | 4 | 7 |
| ivabradine | 1 | - | 4 | 1 | 6 |
| ketamine | 8 | - | - | - | 8 |
| lamotrigine | 10 | - | 5 | 1 | 16 |
| lenalidomide | 6 | - | 1 | - | 7 |
| levetiracetam | 31 | - | - | 1 | 32 |
| levocarnitine | 2 | - | 1 | - | 3 |
| linezolid | 7 | - | - | 1 | 8 |
| liraglutide | - | - | 6 | - | 6 |
| macitentan | 7 | - | 3 | 1 | 11 |
| melatonin | - | - | 4 | - | 4 |
| mepolizumab | 2 | - | 2 | - | 4 |
| mitotane | 10 | - | - | - | 10 |
| moxifloxacin | 4 | - | 1 | 1 | 6 |
| nelarabine | 4 | - | 1 | - | 5 |
| nirmatrelvir with ritonavir | 1 | - | 2 | 5 | 8 |
| octreotide lar | 4 | - | - | 1 | 5 |
| olaparib | 12 | - | 1 | - | 13 |
| omalizumab | 2 | - | 1 | 1 | 4 |
| pazopanib | 3 | - | 2 | - | 5 |
| pembrolizumab | 9 | - | 11 | 1 | 21 |
| pirfenidone | - | - | 1 | 3 | 4 |
| posaconazole | 9 | - | 1 | - | 10 |
| pristinamycin | 7 | - | - | - | 7 |
| prucalopride | 6 | - | 6 | 1 | 13 |
| retinol (vitamin a) | 55 | - | - | - | 55 |
| rituximab | 26 | - | 5 | 3 | 34 |
| rufinamide | 7 | - | 1 | - | 8 |
| ruxolitinib | 4 | - | 2 | - | 6 |
| sargramostim | 4 | - | - | - | 4 |
| secukinumab | 7 | - | 3 | - | 10 |
| sirolimus | 4 | - | - | - | 4 |
| sunitinib | 2 | - | 1 | 1 | 4 |
| tacrolimus ointment | 1 | - | - | 4 | 5 |
| tadalafil | 3 | - | 3 | 1 | 7 |
| temozolomide | 10 | - | 3 | - | 13 |
| thalidomide | 4 | - | 1 | - | 5 |
| tocilizumab | 7 | - | 9 | 1 | 17 |
| topotecan | 5 | - | - | - | 5 |
| trametinib | 16 | - | 1 | 1 | 18 |
| upadacitinib | 12 | - | 5 | 1 | 18 |
| ustekinumab | 1 | - | 3 | - | 4 |
| valganciclovir | 4 | - | - | - | 4 |
| varicella zoster vaccine | - | - | 5 | 1 | 6 |
| venetoclax | 5 | - | 5 | 1 | 11 |
| voriconazole | 7 | - | - | 1 | 8 |
| zonisamide | 8 | - | 1 | - | 9 |
| Grand Total | 632 | 1 | 158 | 59 | 850 |